SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCath reimbursement could fall sharply in 2027 has fueled concern about pricing and sales for CorMedixs flagship product, alongside a steep selloff. Traders disagree over whether the warning signals lasting pressure or is a preliminary, DaVita-specific estimate that overstates the risk; some view the decline as panic selling and point to CMS reimbursement figures as a counterpoint.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Oktas selection for S&P 500 inclusion is drawing attention, with traders anticipating demand from index-tracking funds while debating whether that buying is already priced in and could be followed by profit-taking. The discussion also weighs the inclusion-driven momentum against concerns about Oktas valuation and slower growth.

NEOS ETF Trust - NEOS Nasdaq 100 High Income ETF

NEOS Nasdaq 100 High Income ETF

A broader market and Nasdaq-led tech selloff has pressured QQQI, prompting many holders to add on the dip while others raise cash or worry about further downside. The debate is set against the ETFs appeal as a high-income, monthly-distribution fund and concerns that covered-call exposure can limit upside or leave the fund vulnerable in a downturn.

Cameco Corp. engages in the provision of uranium. It operates through the following segments: Uranium and Fuel Services. The Uranium segment is involved in the exploration for, mining, milling, purchase, and sale of uranium concentrate. The Fuel Services segment deals with the refining, conversion, and fabrication of uranium concentrate and the purchase and sale of conversion services. The company was founded in 1988 and is headquartered in Saskatoon, Canada.

Cameco Corp.

Camecos Q3 report, including lower results and narrowed 2026 production guidance amid Cigar Lake production concerns, is driving the selloff. Traders are split between viewing the update and uranium-sector weakness as reasons for further downside and treating the pullback as an opportunity, citing long-term nuclear demand and firm uranium prices.

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Agenus Inc

Agenus is drawing attention for encouraging early BOT+BAL immunotherapy data, including high pathologic response rates in a small Phase 2 colon cancer cohort and reported activity in sarcoma. The community is divided: bulls see potential for the treatment and its broader platform, while skeptics point to small, nonrandomized studies, the need for Phase 3 validation, and dilution and execution concerns.

Mattel, Inc. engages in the ownership of children's and family entertainment franchises. It operates through the following segments: North America, International, and American Girl. The North America and International segments focus on marketing and selling toys and consumer products. The American Girl segment includes marketing, retailing, and publishing dedicated to its mission to help girls grow up with confidence and character. The company was founded by Elliot Handler, Ruth Handler, and Harold Matson in 1945 and is headquartered in El Segundo, CA.

Mattel, Inc.

Reported takeover interest from Authentic Brands Group, alongside activist pressure for Mattel to consider a sale, is driving the discussion; no formal deal is confirmed. Traders are weighing potential acquisition upside against the risk that the takeover buzz fades without a firm bid.

United States Natural Gas Fund LP. - United States Natural Gas Fund

United States Natural Gas Fund, LP

Mild-weather forecasts and ample storage are weighing on natural gas prices by tempering expectations for heating demand. Traders are split between bearish views citing a potentially warm winter and surplus inventories, and dip-buyers betting on colder forecasts or a winter-driven rebound.

FuelCell Energy, Inc. is an American clean energy technology company that delivers continuous, scalable baseload power for mission-critical applications globally. It engages in the development, design, production, construction, operation, and servicing of high-temperature fuel cells for clean electric power generation. The company’s fuel cell systems generate electricity directly at the point of use, enabling reliable, low-emission power for data centers, industrial facilities, utilities, and distributed generation customers. FuelCell Energy delivers commercially proven, modular, utility-scale systems backed by global fuel cell deployments approaching one gigawatt. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FCEL is under pressure after traders criticized CEO Jason Fews Bloomberg appearance and flagged his expectation of a delay in signing the Texas definitive contract, alongside uncertainty about the promised 100 MW production ramp. Some investors remain focused on potential data-center demand and the Newport project, while others say execution delays and weak shareholder communication are undermining confidence.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

A newly disclosed convertible-note financing and proposed increase in authorized shares have fueled concerns about heavy dilution, triggering sharp selling and criticism of managements communication. Some traders see the funding as necessary to advance data-center projects, while others worry that ongoing cash needs could bring further dilution.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disneys better-than-expected quarterly results, supported by parks strength and improving streaming profitability, have renewed bullish interest and fueled breakout chatter. Traders remain divided, with optimists pointing to stronger execution and skeptics citing years of range-bound performance and nearby resistance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple Myeloma

$2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple Myeloma $2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple MyelomaPR NewswireTEL...

Weekly Losses Deepen As Small Caps Lag And Yields Edge Higher Into Earnings Gauntlet

Weekly Losses Deepen As Small Caps Lag And Yields Edge Higher Into Earnings Gauntlet Weekly Losses Deepen As Small Caps Lag And Yields Edge Higher Into Earnings GauntletPR NewswireNEW YORK, Oct. 1, 2026Stock Preachers News CommentaryNEW YORK, Oct. 1, 2026 /PRNewswire/ --Stocks closed out a choppy...

RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results

RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial ResultsPR NewswireTEL AVIV, Israel and RALEIGH, N.C., Sept. 30, 2026Executing a full strategic portfolio reset, RedHill is now a...

12 Health Care Stocks Moving In Monday's Intraday Session

Gainers

Redhill Biopharma (NASDAQ:RDHL) stock increased by 69.4% to $1.12 during Monday's regular session. The company's market cap stands at $4.0 million.
CollPlant Biotechnologies (NASDAQ:CLGN) sharesread more...

Pharma Junior Rallies 66% as Asset Monetization Unlocks $18M Upfront Cash

An upfront cash infusion from a commercial asset sale sparked a massive morning rally in specialty pharma today, highlighting how non-dilutive liquidity events can rapidly re-rate microcap balance sheets. When a developer monetizes its majority stake in an approved drug to a global manufacturing partner, the market quickly rewards the immediate cash injection. RedHill Biopharma Ltd. (Nasdaq: RDHL) advanced Monday after divesting its Talicia business to a subsidiary of Apotex Health Corp. (TSX: APTX) for $18M in cash upfront, plus up to additional $35M tied to worldwide net-sales ...

Redhill Biopharma Stock Doubles In One Session  Here's Why

RedHill Biopharma divests Talicia to Apotex, boosting liquidity and funding its commercial growth strategy and RHB-102 development.read more...

RedHill Cashes Out of Talicia: $18M Upfront Deal Hands H. pylori Franchise to Apotex and Funds a GI Reset

RedHill Biopharma (NASDAQ:RDHL) just sold the product that defined its U.S. commercial identity. RedHill announced it divested its remaining 70% stake in Talicia to a subsidiary of newly public Apotex Health (TSX:APTX) for $18 million in cash upfront plus up to $35 million in worldwide net sales milestones. Apotex already owned the other 30% after buying Cumberland’s (NASDAQ:CPIX) U.S. branded business earlier this year. The sale consolidates Talicia under one owner and gives RedHill the liquidity it says it needs to rebuild a larger gastrointestinal franchise.

12 Health Care Stocks Moving In Monday's Pre-Market Session

Gainers

Redhill Biopharma (NASDAQ:RDHL) shares increased by 96.7% to $1.3 during Monday's pre-market session. The market value of their outstanding shares is at $4.0 million.
Vivos Therapeutics (NASDAQ:VVOS) stockread more...

Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development

Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development PR Newswire TEL AVIV, Israel and RALEIGH, N.C., July 28, 2026 The number of confirmed Ebola cases and...

RedHill Biopharma Ltd. engages in the development and commercialization of drugs for gastrointestinal (GI), infectious diseases, and oncology. The firm's products include Talicia, Movantik, and Aemcolo. It operates through the Commercial Operations and Research and Development segments. The Commercial Operations segment covers areas relating to commercial sales through a subsidiary in the United States. The Research and Development segment includes the study and licensing of therapeutic candidates. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.

Redhill Biopharma Ltd. - ADR

RedHill Biopharma Logs Best Session In Over A Year After $10M Legal Victory — Retail Sees Bullish Triggers Ahead

Equity

Bearish Sentiment

RedHill Biopharma’s&nbsp;stock recorded its best trading session in more than a year on Monday after the New York Supreme Court upheld a $10 million award in the company’s ongoing legal dispute with Kukbo.Shares of the company jumped 27.2%, to close at $2.34 on Monday, before slipping 7.1% to $2.17 in after-hours trading.The Court reaffirmed its original summary judgment ruling in favor of RedHill, dismissing Kukbo’s appeal and the entirety of its defense. It ruled that Kukbo breached both the subscription and exclusive license agreements signed with RedHill in 2021 and 2022 and that RedHill had properly fulfilled its obligations, even after Kukbo’s non-payment.The total award amounts to approximately $10 million,&nbsp;comprising the original judgment of $8.25 million and an additional $1.82 million granted in August 2025 for legal costs and expenses. Both awards carry a 9% ongoing statutory interest accrual. Kukbo retains the right to further appeal the ruling.In addition to the U.S. court ruling, RedHill also secured a court-ordered seizure of Kukbo’s assets in May 2025 from Korea’s Incheon District Court, freezing those assets following the initial $8.25 million award and preventing their disposal before judgment enforcement. In August, RedHill received an additional $1.82 million for legal expenses.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 9,900% surge in 24-hour message volume.One user stated that short sellers were likely to get squeezed, arguing that RedHill’s market capitalization of approximately $7 million was significantly below the $10 million court award and calling the stock undervalued, with a fair price between $5 and $7.<stembedurl>https://stocktwits.com/PeterTauscher/message/630386393</stembedurl>Another user reported an increase in their position, noting that several potential catalysts could drive the stock higher in the coming months.<stembedurl>https://stocktwits.com/Imatron12/message/630390832</stembedurl><a href="https://stocktwits.com/symbol/RDHL">RedHill Biopharma’s stock</a> has declined 62.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

RedHill Biopharma’s stock (RDHL) has declined 62.3% so far in 2025. (Photo credit: Getty Images)

The stock rallied after the New York Supreme Court reaffirmed RedHill’s $10 million award in its dispute with Kukbo.

RedHill Biopharma Ltd.

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$0.3878
Prev Close	$0.4166
Open	$0.3995
Dividend Yield	0.00%
50-Day Moving Average	$0.5566
Beta	0.80
Avg. Volume	443,403.80
PE Ratio	0.00

52-Week High	$1.60
52-Week Low	$0.3801
Market Capitalization	$3.45M
EPS (Annual)	-$0.1008
Price to Book	-2.19
Revenue Per Employee	$22,174.54

Feed

News

Sentiment

Fundamentals

Info

RDHL Fundamentals